Current perspectives in HIV post-exposure prophylaxis

Binta Sultan1,2
Paul Benn1
Laura Waters1

1Department of Genitourinary Medicine, Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK;
2Centre for Sexual Health and HIV Research, University College London, London, UK

Abstract: The incidence of human immunodeficiency virus (HIV) infection continues to rise among core groups and efforts to reduce the numbers of new infections are being redoubled. Post-exposure prophylaxis (PEP) is the use of short-term antiretroviral therapy (ART) to reduce the risk of acquisition of HIV infection following exposure. Current guidelines recommend a 28-day course of ART within 36–72 hours of exposure to HIV. As long as individuals continue to be exposed to HIV there will be a role for PEP in the foreseeable future. Nonoccupational PEP, the vast majority of which is for sexual exposure (PEPSE), has a significant role to play in HIV prevention efforts. Awareness of PEP and its availability for both clinicians and those who are eligible to receive it are crucial to ensure that PEP is used to its full potential in any HIV prevention strategy. In this review, we provide current evidence for the use of PEPSE, assessment of the risk of HIV transmission, indications for PEP, drug regimens, and management of patients started on PEP. We summarize national and international guidelines for the use of PEPSE. We explore the place of PEP within the wider strategy of reducing HIV incidence rates in the era of treatment as prevention and pre-exposure prophylaxis. We also consider the implications of recent data from interventional and observational studies demonstrating significant reductions in the risk of HIV transmission within a serodiscordant relationship if the HIV-positive partner is taking effective ART upon PEP guidelines.

Keywords: post-exposure prophylaxis, pre-exposure prophylaxis, treatment as prevention, human immunodeficiency virus

Introduction

Different strategies for human immunodeficiency virus (HIV) prevention including earlier HIV diagnosis and the use of antiretroviral therapy (ART) to prevent transmission of HIV (treatment as prevention [TasP] and pre- and post-exposure prophylaxis [PrEP and PEP]) are of considerable interest. The Joint United Nations Programme on HIV and AIDS (UNAIDS) declaration on HIV and AIDS in 2011 confirms that HIV prevention must remain the cornerstone of the HIV response. PEP is the use of short-term ART to reduce the risk of acquisition of HIV infection following exposure. It is widely available following occupational exposure to HIV and has become increasingly available for nonoccupational exposure to HIV.

HIV incidence and prevalence

The number of people with newly acquired HIV infection continues to rise, with 2.3 million new infections worldwide in 2012. There is a resurgence of the HIV epidemic among men who have sex with men (MSM) in North America and...
Western Europe. Between 2000 and 2006 there was an 86% rise in the annual number of new HIV diagnoses in this risk group. It is essential for HIV prevention efforts to maintain their intensity and that novel ways of preventing HIV infection are incorporated into existing strategies in order to reduce the incidence of HIV infection.

Nonoccupational PEP, the vast majority of which is for sexual exposure (PEPSE), has a role to play in these prevention efforts. This review will focus mainly on PEPSE but can also be applied to any other nonoccupational PEP.

Rationale for PEP
It may take up to 72 hours for HIV to be detected in regional lymph nodes, up to 5 days to be detected in blood, and about 8 days to be detected in the cerebrospinal fluid. This offers a window of opportunity to prevent acquisition of HIV infection following exposure by inhibiting viral replication or preventing dissemination of infection, if ART is started early.

Evidence for PEP
Much of the data for PEP efficacy comes from animal models. Data from retrospective analyses of PEP for occupational exposure as well as vertical (mother-to-child) transmission studies add to the evidence base for HIV PEP. Based on this data, PEPSE is likely to be effective.

Animal models
Most animal models have shown benefit of PEP in terms of preventing HIV acquisition. However, comparisons between these studies are difficult as they use different retroviruses, inocula volumes, and modes of transmission.

A recent macaque study of intermittent PrEP and PEP with oral combined tenofovir and emtricitabine (Truvada®, Gilead Sciences, Foster City, CA, USA) following rectal inocula demonstrated that a post-exposure dose was essential to prevent infection. The greatest protection was achieved with the first Truvada dose between 22 hours and 7 days pre-exposure, with the second dose 2 hours post-exposure.

Other studies have shown that 28 days subcutaneous tenofovir administered to macaques after intravenous or intravaginal exposure prevented 100% of infections if given within 24 or 36 hours, respectively. The proportion of macaques infected increased with: 1) longer intervals to tenofovir administration (no protection if administered 72 hours post-exposure); or 2) decreased duration of treatment.

One study showed no protection from triple PEP after intravenous inoculation which may have been due to the inoculum size or route of administration.

Human studies
Vertical transmission
Studies illustrating a reduction in vertical transmission of HIV with antiretroviral treatment of pregnant women also support the efficacy of PEP. In AIDS Clinical Trials Group (ACTG) 076, reduced incidence of HIV was observed in neonates given 6 weeks of zidovudine within 48 hours of delivery to women who had not received any ART prior to delivery. Recent evidence in pregnant women who had not received ART suggests that dual or triple ART for the neonate is more effective than monotherapy in preventing mother-to-child transmission.

Occupational exposure to HIV
There are no prospective randomized controlled trials of PEP efficacy due to the ethics of withholding a potentially efficacious treatment and the difficulty in recruiting the high number of participants that would be required for such a study.

Much of the rationale for PEP use in humans is derived from a case-control study of health care workers occupationally exposed to HIV, which demonstrated that a 28-day course of zidovudine was protective (odds ratio [OR]: 0.19, 95% confidence interval [CI]: 0.06–0.52). This study has limitations, including a small number of cases (n=33); also, cases and controls (n=665) were derived from different countries and data on exposure characteristics were collected retrospectively. To date, there are at least 24 cases of PEP failure following occupational exposure, mostly after the use of zidovudine monotherapy.

PEPSE
There is a paucity of data regarding the efficacy of PEPSE and no randomized controlled trials. An observational PEPSE study undertaken in Brazil among MSM provided with PEP for use after a high-risk exposure demonstrated fewer HIV seroconversions among individuals taking PEPSE compared to those who did not; however, the study also found that people did not estimate their own risk well. When they took PEP, it was effective but the overall HIV incidence remained unchanged compared with historical rates because they did not access PEP after other high-risk episodes. A recent systematic review of PEPSE concluded that it was not possible to determine its effectiveness due to the lack of evidence, although it may be cost-effective in certain circumstances.

Assessment of the risk of HIV transmission
Risk of HIV transmission = risk that source is HIV-positive × risk of exposure
(*including cofactors such as sexually transmitted infections (STIs), high viral load, and bleeding).
The decision to initiate PEP should be based upon a risk/benefit analysis weighing up the risk of an individual acquiring HIV and the potential for harm due to PEP. This risk of transmission is determined by the risk that the source is HIV-positive and the type of exposure (Table 1). Risk of HIV transmission is greatest for blood transfusions, followed by vertical exposure, sexual exposures, and other parenteral exposures. Sexual exposure accounts for the majority of HIV infections, with much variability in the risk of acquiring HIV depending on the specific sexual act. The risks from sexual exposure ranged from low for oral sex to 138 infections per 10,000 exposures for receptive anal intercourse.\textsuperscript{18,19} Unprotected receptive anal intercourse (UPRAI) and sharing needles have the highest risk of acquiring HIV per exposure. Insertive anal intercourse (IAI) and vaginal intercourse (receptive and insertive) and oral sex are described as having lower per-act risks.

Anal intercourse
An Australian cohort study\textsuperscript{19} estimated that the per-contact probability of HIV transmission in MSM through UPRAI was 1.43% with ejaculation and 0.65% without ejaculation. The risk through IAI was 0.62% in uncircumcised men and 0.11% in circumcised men. A meta-analysis\textsuperscript{19} demonstrated a per-act risk of UPRAI of 1.4%, with no significant difference between heterosexuals and MSMs. They also showed that there was much variability in the risks of anal intercourse, and that it may increase the risk of transmission even when the partner is on ART.

Vaginal intercourse
A European study estimated the risk of receptive vaginal intercourse to be 0.08%, and insertive vaginal intercourse to be 0.04%.\textsuperscript{20} This risk is reduced when the partner is on effective ART.\textsuperscript{21} Caution should be used in using these estimates as heterosexual infectivity is variable and thought to be underestimated,\textsuperscript{22} and cofactors such as genital ulcer disease have a significant impact on transmission risks.

### Oral intercourse
There has been some observational data that HIV can be transmitted through oral intercourse, but the risks are difficult to estimate, due to the likelihood of other concurrent sexual risk exposures, and are thought to be very low. A study estimated a per-act risk of receptive oral intercourse with ejaculation at 0.06% with an HIV-positive partner or partner of unknown status, with no increased risk with insertive oral intercourse.\textsuperscript{23}

Where the HIV status of the source is unknown, it is important to consider the local HIV prevalence within the relevant risk groups.

### The HIV status of the source individual
The HIV status of the source individual is key to determining the risk of HIV acquisition for the person exposed, and thereby, whether PEP is indicated. It is important that active attempts are made to determine the HIV status and treatment history of the source individual. This is often not possible, particularly in the cases of sexual assault or when casual partners are untraceable. If it is not possible to determine the HIV status of the source, assumptions about their HIV risk must be made based on demographic characteristics, which will vary from region to region. In the UK, MSM and heterosexuals from Sub-Saharan Africa have the greatest likelihood of being HIV-positive\textsuperscript{24} and are considered higher risk individuals.

The risk of HIV transmission is highest in those people who have had blood or mucosal exposure to someone who is HIV-positive and with a detectable viral load. UPRAI remains the highest sexual risk exposure for HIV acquisition. The previously listed cofactors may influence the risk of HIV transmission and should be taken into account when determining whether an individual should receive PEPSE.

Other factors may influence the risk of HIV transmission; these include:

1. High plasma viral load in the source: this may be particularly relevant during primary HIV infection, which accounts for a significant proportion of new infections.\textsuperscript{25,26} UK guidelines now recommend that the risk of HIV transmission and the protection conferred by effective ART should be discussed with HIV-positive patients – this is highlighted also as a reason to consider starting HIV treatment during primary HIV infection.\textsuperscript{27}

Low or undetectable plasma viral loads reduce the risk,
but transmission may still be possible. Viral loads in the genital tract usually correlate with plasma viral loads, but there can be exceptions and viral suppression in the genital compartment may lag behind plasma. The HIV Prevention Trials Network (HPTN) study demonstrated that early initiation of ART results in a 96% relative risk reduction of HIV transmission in serodiscordant couples. Results of the PARTNERS study presented at the Conference on Retroviruses and Opportunistic Infections (CROI), showed no HIV transmissions to date between serodifferent MSM and heterosexual couples where the HIV-positive partner had an undetectable HIV viral load; the predicted number of transmissions had the partner living with HIV not been treated was 86.

2. STIs: there is evidence that STIs enhance HIV transmission and increase HIV shedding from the genital tract. This may not be the case in individuals receiving effective ART.

3. Breaches in the mucosal barrier: this includes mouth or genital ulcer disease and trauma.

4. Exposure to blood: menstruation or other bleeding may also facilitate transmission.

5. Ejaculation: the risk of HIV transmission is likely to be greater if ejaculation occurs. Among a community cohort of MSM, the risk of HIV acquisition per episode of UPRAI with and without ejaculation was estimated to be 1.43% (95% CI: 0.48–2.85) and 0.65% (95% CI: 0.15–1.53), respectively.

6. Circumcision: circumcision significantly reduces HIV acquisition among heterosexual men in high prevalence countries. A meta-analysis of observational studies among MSM suggests circumcision may have little impact upon HIV acquisition, as receptive anal intercourse is the key driver of transmission. However, there may be benefit for MSMS who exclusively or almost exclusively practice IAI. An Australian cohort showed a reduction in per-act risk of HIV transmission from 0.62% in uncircumcised MSM to 0.11% in circumcised MSM. Data from observational studies suggest a 73% relative risk reduction for men who are circumcised and practice mainly IAI.

Factors that influence the efficacy of PEP

Individuals have acquired HIV following both occupational and sexual exposures, despite the use of PEP. Therefore, PEP is not 100% effective.

Various factors that influence PEP effectiveness include:
- Time to starting PEP
- Incomplete adherence/non-completion
- Source virus
- Penetration of drugs into tissue compartments
- Further high-risk sexual exposures

Time to starting PEP

PEP is likely to be ineffective if initiated more than 72 hours after exposure; the majority of international guidelines do not recommend PEP provision after this time, and other guidelines recommend even shorter window periods. New York State guidelines recommend nonoccupational PEP is given no more than 36 hours after exposure. This discrepancy exists as there has been no prospective trials in humans to assess the optimal time for commencement of PEP after an exposure. However, the data from animal studies provide strong evidence of increasing rates of failure of PEP by 48–72 hours after exposure.

One animal study showed that when time to treatment was extended to 48 and 72 hours post-exposure, half the animals in both groups were persistently infected.

Another study investigated 28 days of tenofovir started at different post-exposure intervals in vaginally exposed macaques; only one seroconversion in an animal started on PEP 72 hours post-exposure was found compared to none in the 24- and 48-hour post-exposure groups; this was a statistically significant finding (Fisher’s exact test, P=0.018).

Occupational guidelines recommend that PEP is commenced as soon as possible after the exposure. The time to initiating PEPSE is often longer than for occupational exposure. This may be as a consequence of both delays in patients seeking PEP as well as the provision of PEP by health care professionals.

Adherence to PEP

Adherence and completion rates of 4 weeks of PEP among health care workers and individuals exposed nonoccupationally are often poor, which may impact upon its efficacy. Pill burden and the side effects of treatment may influence completion rates. Other factors such as psychological distress and re-evaluation of risk may also impact PEP completion.

A recent systematic review of PEP use in victims of sexual assault showed poor adherence, with better completion rates in developing countries. Unmeasured factors such as stigma associated with sexual assault may play a role in this.
However, in a recent meta-analysis of PEP in non-forcible exposure to HIV, taking into account those that were lost to follow-up, found that 67% of people completed a 28-day course of PEP. This was higher in groups that had counseling throughout the course of treatment.\textsuperscript{46} Psychological and social support are important adjuncts to effective PEP services.

**Drug resistance in the source**

PEP efficacy may be compromised if the source has a virus that is resistant to one of the agents used.\textsuperscript{49} The prevalence of antiretroviral resistance among those with primary HIV infection and those chronically infected with HIV has plateaued at 8% in the UK and Europe,\textsuperscript{50,51} but this is not the case in low- and middle-income countries. A meta-analysis has demonstrated a significant increase in the prevalence of drug resistance over time since antiretroviral rollout in regions of Sub-Saharan Africa.\textsuperscript{52} If the source is known or suspected to have drug resistance, the PEP regimen should be tailored accordingly.

**Drug penetration into tissue compartments**

There is evidence that, even with optimal viral suppression in the blood, HIV can be detected in other tissue compartments.\textsuperscript{53} As different antiretroviral agents penetrate these compartments to different degrees,\textsuperscript{54} the choice of drugs used in PEP could influence its efficacy.

**Risks of PEP**

The risks of starting PEP are summarized below:

1. Drug side effects: all ART can cause side effects, which should be considered carefully and discussed before starting PEP.\textsuperscript{55} Symptoms, such as diarrhea, are one of the main reasons for nonadherence and discontinuation of PEP. Drug side effects are discussed further in the section describing the various antiretroviral options for PEP.

2. Behavioral and psychological implications: despite concerns that PEPSE and PrEP availability will reduce individual commitment to other primary prevention strategies, such as condoms and behavioral interventions,\textsuperscript{56,57} there is little evidence of increased risk behavior among individuals with access to PEP;\textsuperscript{58,59} and in a large randomized trial of PrEP, there was a reduction in risky behavior.\textsuperscript{60} The impact of open-label PrEP use upon risk compensation has yet to be determined. The availability of PEPSE in clinics provides an opportunity to offer health education, health promotion, risk reduction strategies, and HIV prevention strategies such as PrEP to high-risk individuals who may not access services otherwise.

3. Drug resistance: there is a potential risk of drug resistance developing in those who fail to complete PEP and acquire HIV. Poor adherence was a risk for subsequent seroconversion in a retrospective analysis of PEPSE failures.\textsuperscript{46} It is likely that adherence and treatment completion rates will be better with more tolerable PEP regimens.

**Choice of ART**

The choice of drugs to be used for PEP is based on those used to treat established HIV infection.

For HIV therapy, combination drug therapy with at least three drugs is more effective than single drug regimens. Consensus guidelines for chronic HIV infection recommend three drugs from at least two drug classes (typically two nucleoside reverse transcriptase inhibitors [NRTI] with a non-nucleoside reverse transcriptase inhibitor [NNRTI], a boosted protease inhibitor [PI/r], or an integrase inhibitor [INI]). Most PEPSE guidelines recommend three drugs for PEPSE based upon the evidence for treating HIV-positive individuals and that late presentation for PEP and the potential for drug resistance in the source make triple therapy likely to be more effective than mono- or dual-therapy PEP.

A recent study has been the first to effectively demonstrate that a two or three drug regimen is more effective than monotherapy for nonoccupational PEP.\textsuperscript{13} This study also showed that dual therapy can be as effective as triple therapy, with no difference in efficacy seen. The cost benefit of adding in a third drug should be considered, but this is a decision that needs to be made in the context of the individual patient, their risks, and the source. Almost all guidelines advise a triple therapy regimen. Expert advice should be sought if the source is known or suspected to have viral resistance.

**NRTI**

Zidovudine (an NRTI) is the only drug to date for which there is evidence of reduced HIV transmission risk following occupational exposure. Combivir\textsuperscript{6} (GlaxoSmithKline plc, London, UK), a fixed dose combination of zidovudine and lamivudine (another NRTI) was frequently used for PEP. Combivir is commonly associated with side effects, particularly gastrointestinal, which may contribute to poor adherence. The routine use of abacavir is not recommended. A hypersensitivity reaction is reported in up to 8% of patients with established infection.\textsuperscript{61,62}

Truvada (a fixed dose combination of tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]; Gilead Sciences) is better tolerated than Combivir with fewer side effects, so is often a first choice PEP component. Both TDF and FTC
penetrate the genital tract and rectal tissue well in animal models.7 Truvada has been shown to significantly reduce acquisition of HIV when used as PrEP in MSM,60 although studies in heterosexuals are conflicting.63–66

NNRTIs

Nevirapine has been associated with significant toxicity (particularly hepatic) as PEP and is not recommended.55,67 Efavirenz has a lower incidence of hepatic and cutaneous toxicity, but as it may be associated with significant central nervous system disturbance, it is not an ideal choice for PEP.

Newer NNRTIs, etravirine and rilpivirine, are well-tolerated, although rash is common on etravirine and there have been case reports of severe rash in HIV-positive individuals.68 Rilpivirine causes rash less commonly and is currently being evaluated as PEP.69

Protease inhibitors

It is likely that PEP is aborting and inhibiting replication and dissemination rather than preventing infection and that part of this activity will be achieved by rendering new virions non-infective. Therefore, although PI/Is act at a post-integrational stage of the HIV life cycle, they should still provide benefit as PEP.

Nelfinavir, lopinavir/ritonavir (LPV/r), atazanavir/ritonavir (ATV/r), and more recently darunavir/ritonavir70 have all been used or evaluated as PEP.

PIs have been associated with metabolic abnormalities as well as gastrointestinal side effects. Kaletra® (Abbott Laboratories, Abbott Park, IL, USA), a fixed dose combination of LPV/r is the recommended PI for inclusion with PEP regimens in the UK,71,72 but commonly causes diarrhea.71

Although newer PIs have better gastrointestinal tolerability than LPV/r in treatment trials, a recent randomized comparison of ATV/r versus Kaletra-based PEP,73 each with Combivir, revealed similar and high discontinuation rates (36% in each arm) and similar discontinuation rates secondary to PI side effects (16% due to LPV/r and 17% due to ATV/r). An Australian study compared PI-based PEP (Combivir plus nelfinavir – an unboosted PI no longer routinely used) with a triple NRTI combination (TDF, lamivudine, and stavudine).74 Although the triple NRTI regimen was more frequently associated with peripheral neuropathy and transaminitis, discontinuations were significantly less frequent than on PI-based PEP.

There is also an increased risk of drug–drug interactions with the use of PIs. A recent PEP study found that almost half of the participants were regularly taking at least one prescribed medication. These included corticosteroids, anticonvulsants, antidepressants, anti-lipids, and anti-hypertensives, which are known to have potential drug interactions with PIs.75 It is important to consider drug–drug interactions with prescribed and nonprescribed drugs, including recreational drugs when selecting the best PEP regimen.

Other drug classes

Raltegravir (RAL), an INI, has a favorable tolerability, safety, and metabolic profile,76 and is well-tolerated as PEP.75,77 It acts before viral integration and thus may be more effective at preventing HIV infection. It has fewer side effects and fewer drug–drug interactions than other classes of antiretroviral medications. The New York State Department of Health recently started using RAL, FTC, TDF as its first-line occupational and nonoccupational PEP regimen, and the Center for Disease Control (CDC) now recommends the use of RAL for occupational PEP.78 A recent interventional study assessed RAL as part of a triple drug PEP regimen, including FTC and TDF, in comparison to FTC and TDF.79 Researchers found the RAL regimen had a high completion rate, was effective, and avoided potential drug–drug interactions. However, there was a small risk of acute muscle toxicity. Two other INIs, elvitegravir and dolutegravir, have been licensed recently. Elvitegravir is currently being evaluated as PEP in a study in the US using Stribild® (elvitegravir/cobicistat/emtricitabine/TDF; Gilead Sciences); however, cobicistat has similar drug–drug interactions as ritonavir.79

Maraviroc (MVC), the only licensed CCR5 antagonist, also performs well from the perspectives of safety and tolerability.80 HIV can use one of two co-receptors, CCR5 or CXCR4, to enter host cells. Although MVC only inhibits CCR5, there is evidence that the majority of transmitted HIV uses this co-receptor, indicating MVC could be a useful PEP option. Studies investigating MVC as PEP and PrEP options are ongoing.81,82 There is also evidence that both RAL and MVC penetrate the genital tract and rectal mucosa well;83–87 this may be an important consideration for PEP. More data is required as to their efficacy, although, consistent with national guidance, many centers use RAL for PEP cases where drug–drug interactions or tolerability problems preclude the use of LPV/r. Considerations include resistance and cost-effectiveness.

The UK British Association for Sexual Health and HIV (BASHH) PEPSE guidelines71 recommend Truvada and Kaletra for 28 days (Table 2) but are currently being reviewed. The guidelines also make recommendations for alternative agents in the event of intolerance, drug–drug interactions, or resistance in the source. US guidelines for nonoccupational
PEP prefer TDF, lamivudine, and RAL; LPV/r; or EFV with 3/FTC, and list several regimens as alternatives.\(^8\)

**Side effects and toxicity**

As aforementioned, antiretrovirals may be associated with side effects and in some cases are tolerated less well by HIV-negative individuals. Symptomatic management may improve tolerability of PEP, and most clinics offer antiemetics and antiemetic medications with PEP starter packs. Proximal renal tubular dysfunction and Fanconi’s syndrome have been reported in HIV-positive patients receiving tenofovir; although this has not yet been reported in the setting of Truvada use as PEP or PrEP,\(^9\)\(^9\)\(^,\)\(^9\)\(^3\) monitoring is still required (Table 3).

PEP follow-up data from 140 patients in Brighton, UK, showed 71\% developed new blood abnormalities. All except one, showed grade 1 or 2 elevation in alanine transaminase (ALT), one had a grade 3 elevation of ALT (but had a history of excess alcohol use). There have been no reports of Fanconi’s syndrome to date in these patients.\(^9\)\(^2\) Recent data from a clinic in London showed 13\% of people had significant abnormalities at a median onset of 6 days (range 0–28 days).\(^9\)\(^3\) This evidence supports regular monitoring throughout the course of PEP in order to detect these abnormalities, consistent with guidelines.\(^7\)\(^1\)

The majority of these biochemical abnormalities normalize on stopping PEP, and require no further follow-up.

**Duration of treatment**

The optimal duration of PEP is unknown and there have not been any randomized controlled trials assessing the effectiveness of PEP with suboptimal adherence to the regimen. There have been small animal studies that have suggested 28 days is optimal\(^8\) and a case-control study of health care workers\(^1\)\(^4\) showed failure of PEP when the 28 days of treatment was not completed. Therefore, current guidelines recommend that 4 weeks of PEP should be used.

**Potential for drug–drug interactions**

It is essential to ensure that the potential for drug–drug interactions is considered with the use of PEP. Clinicians are advised to liaise with an HIV specialist pharmacist and/or use online tools such as [http://www.hiv-druginteractions.org/](http://www.hiv-druginteractions.org/) for this purpose. Individuals should also be warned about interactions with over-the-counter and recreational drugs.

**Current guidelines for PEPSE**

Guidelines for starting PEPSE differ by region and are compared in Table 4. UK and US guidelines advise starting PEP before 72 hours of exposure, whereas the European AIDS Clinical Society (EACS) advises starting before 48 hours of exposure.\(^7\)\(^1\)\(^,\)\(^7\)\(^3\)\(^,\)\(^7\)\(^4\) These guidelines recommend the use of PEPSE following unprotected anal or vaginal sex with someone known or likely to have HIV. The recently updated UK BASHH guidelines\(^7\)\(^1\) recommend that PEPSE is: 1) indicated when the estimated transmission risk is 1 in 1,000 or greater; 2) considered when the estimated transmission risk is between

### Table 2 Recommended combinations for PEP according to the BASHH guidelines 2011

<table>
<thead>
<tr>
<th>Recommended combination</th>
<th>Truvada(^6) (TDF plus FTC) one tablet once daily(^7) and Kaletra(^8,9) (ritonavir and lopinavir) two tablets twice daily or four tablets once daily for 28 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternative nucleoside analogs</td>
<td>Stavudine 30 or 40 mg twice daily (according to weight) or Zidovudine 250 mg twice daily(^4) plus Emtricitabine 200 mg once daily or Lamivudine 300 mg once daily(^4)</td>
</tr>
<tr>
<td>Alternative protease inhibitors</td>
<td>Atazanavir 300 mg once daily plus Ritonavir 100 mg once daily or Darunavir 800 mg once daily plus Ritonavir 100 mg once daily</td>
</tr>
<tr>
<td>Alternative to protease inhibitors, eg, in cases with significant drug–drug interactions</td>
<td>Stavudine 30 or 40 mg twice daily (according to weight) or Zidovudine 250 mg twice daily or Raltegravir 400 mg twice daily</td>
</tr>
</tbody>
</table>

**Notes:** Truvada\(^6\) is the preferred agent due to pharmacokinetic considerations, tolerability and the evidence base of efficacy based on animal models for the components, ie, TDF and FTC. Alternative protease inhibitors; Alternative to protease inhibitors; *Available as Combivir*\(^8\) (GlaxoSmithKline plc, London, UK), one tablet twice daily. Kaletra\(^9\), Abbott Laboratories, Abbott Park, IL, USA; Truvada\(^6\), Gilead Sciences, Foster City, CA, USA. Data are from BASHH PEP guidelines.\(^6\)

**Abbreviations:** BASHH, British Association for Sexual Health and HIV; FTC, emtricitabine; PEP, post-exposure prophylaxis; TDF, tenofovir disoproxil fumarate.

### Table 3 UK PEP monitoring recommendations

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Days 3–28</th>
<th>Day 42</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBC (if appropriate)</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
</tr>
<tr>
<td>Renal profile</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
</tr>
<tr>
<td>Liver function</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
</tr>
<tr>
<td>Glucose</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
</tr>
<tr>
<td>Lipids</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
</tr>
<tr>
<td>Urine dipstick/uPCR</td>
<td>✓</td>
<td>✓</td>
<td>–</td>
</tr>
<tr>
<td>PT</td>
<td>✓</td>
<td>±</td>
<td>–</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>✓</td>
<td>–</td>
<td>✓</td>
</tr>
<tr>
<td>Syphilis</td>
<td>✓</td>
<td>–</td>
<td>✓</td>
</tr>
</tbody>
</table>

**Note:** Data are from BASHH PEP guidelines.\(^6\)

**Abbreviations:** FBC, full blood count; PEP, post-exposure prophylaxis; PT, prothrombin time; uPCR, urine protein/creatinine; ✓, recommended; –, not recommended; ±, is indicated.
Table 4 Comparison of Regional Guidelines for nonoccupational PEP

<table>
<thead>
<tr>
<th>Time to initiation (hours)</th>
<th>Source HIV status</th>
<th>Unknown high prevalence group/area</th>
<th>Unknown low prevalence group/area</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-positive: viral load detectable</td>
<td>HIV-positive: viral load undetectable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASHH</td>
<td>CDC</td>
<td>ASHM</td>
<td>EACS</td>
</tr>
<tr>
<td>&lt;72</td>
<td>&lt;48</td>
<td>&lt;72</td>
<td>&lt;48</td>
</tr>
<tr>
<td>Receptive anal sex</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>Insertive anal sex</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>Receptive or insertive vaginal sex</td>
<td>R</td>
<td>R</td>
<td>R</td>
</tr>
<tr>
<td>Fellatio with ejaculation</td>
<td>C</td>
<td>–</td>
<td>NR</td>
</tr>
<tr>
<td>Fellatio without ejaculation</td>
<td>NR</td>
<td>–</td>
<td>NR</td>
</tr>
<tr>
<td>Sharing of injecting equipment</td>
<td>R</td>
<td>–</td>
<td>R</td>
</tr>
</tbody>
</table>

Notes: Data are a summary of international guidelines. * indicates no specific recommendation. `Three antiretrovirals; `two antiretrovirals; `two antiretrovirals if uncircumcised, consider two drugs if circumcised.

Abbreviations: ASHM, Australian Society of HIV Medicine; BASHH, British Association of Sexual Health and HIV; C, consider; CDC, Center for Disease Control; EACS, European AIDS Clinical Society; HIV, human immunodeficiency virus; NR, not recommended; PEP, post-exposure prophylaxis; R, recommended.

HIV/AIDS - Research and Palliative Care downloaded from https://www.dovepress.com/ by 54.70.40.11 on 25-Jan-2020
For personal use only.

All guidelines advise regular follow-up for the evaluation of side effects and adverse therapy as well as initial and follow-up HIV and hepatitis testing.

1 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

2 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

3 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

4 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

5 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

6 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

7 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

8 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

9 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

10 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

11 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

12 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

13 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

14 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

15 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

16 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

17 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

18 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

19 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

20 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

21 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

22 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

23 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

24 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

25 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

26 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

27 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

28 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

29 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

30 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

31 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

32 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

33 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

34 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

35 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

36 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

37 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

38 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

39 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

40 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

41 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

42 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

43 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

44 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

45 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

46 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

47 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

48 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.

49 All patients who present for PEP should have evaluation of the following:
- HIV status of person presenting for PEP; and
- Determination of HIV status of person presenting for PEP.
2. timing and frequency of exposure;
3. HIV status of source;
4. transmission risk from the exposure;
5. evaluation for sexually transmitted infections, hepatitis, and emergency contraception at initial presentation and during follow-up period;
6. advice regarding safer sex and risk reduction strategies;
7. follow-up to evaluate adherence and side effects of medication.

PEPSE provides one aspect of a larger HIV prevention strategy and should be provided in the context of other preventative measures, including promotion of condom use, counseling, and support around behavior modification in order to reduce future risk.

Awareness of PEP and its availability for both clinicians and those who are eligible to receive it are crucial to ensure that PEP is used to its full potential in any HIV prevention strategy. A recent study among an HIV-positive cohort in London showed that there was only 50% awareness of the availability of PEP overall, and 64% in those who had a detectable HIV viral load. Data from the CDC assessing HIV providers’ prescription of PEPSE in two US districts for their patients were poor, with 59.7% and 39.3% having ever prescribed PEPSE.

The decision to start PEP should be made on a case-by-case basis, addressing the unique risks and benefits for each patient. This should consider the risk of transmission according to exposure and the likelihood of the source being HIV-positive as well as the potential for harm as a result of PEPSE.

The indications for provision of PEPSE will continue to be debated but will be increasingly more discussion about the efficacy and availability of PrEP. This could potentially provide another tool in the strategy of HIV prevention, but further evidence is required and there are ongoing clinical trials to determine the safety and effectiveness of this strategy among different groups. In the meantime, PEPSE is a useful tool in ongoing efforts to reduce the incidence of HIV infection, particularly among risk groups.

**Combination prevention strategies**

Increasingly, the place of PEP lies within a wider combination of prevention strategies, which include biomedical, structural, and behavioral interventions to prevent HIV infection and address the interacting causes of HIV risk and vulnerability. These should be tailored to the local needs of the population and include PEP, PrEP, TasP, and risk behavioral interventions such as condom use. HIV prevention and treatment strategies are interdependent. The failure to focus on those with the greatest risk, to focus resources on primary transmission of HIV, and a lack of structural interventions that focus on the causes of vulnerability has already led to rising rates of HIV infection and will likely continue to do so.

PrEP is another drug-based HIV prevention strategy that has been shown to decrease the risk of HIV acquisition in some trials but not others. iPrEx (Pre-exposure Prophylaxis Initiative), a trial of oral Truvada as PrEP in MSM, demonstrated a 44% reduction in HIV incidence in MSM who were taking PrEP compared to control subjects. The study demonstrated that those who were adherent, based on measured drug levels, had a greater risk reduction, and therefore greater efficacy of PrEP if used as it is prescribed. However, consideration to the cost, feasibility, and the potential for risk compensation behaviors need to be given. TasP utilizes the fact that suppressed plasma viremia is strongly correlated with a significant reduction in HIV infectiousness. This has been shown to be highly effective at an individual level: the HPTN 052 trial demonstrated a significant (96%) reduction in linked HIV transmissions among the couples where the HIV-positive partner was randomized to immediate, as compared to deferred, ART. Data on whether effective HIV therapy and the consequent fall in “community viral load” reduces HIV incidence, have been conflicting. This is likely to result from the disproportionate number of new HIV infections arising from individuals with undiagnosed or primary (therefore untreated) HIV in some epidemics (such as the UK). It is likely that we will need to focus on several factors to reduce new HIV infections, including: reducing the burden of undiagnosed HIV infection, educating patients and clinicians to recognize the symptoms of primary HIV, and starting ART in those who wish to in order to reduce the risk of them transmitting to partners.

Falling rates of HIV infection have been linked to changes in behavioral and societal norms. However, there are still two new infections for every person who is started on HIV treatment. PEP is an important component of prevention strategies, and its role as a public health strategy will evolve as other prevention measures such as PrEP and TasP become more widely available. As long as individuals continue to be exposed to HIV, there will be a role for timely PEP.

**Disclosure**

Paul Benn now works for Gilead Sciences Ltd, UK as a Senior Medical Project Manager in HIV. His contributions to this paper were made while still working as an HIV Consultant at the Mortimer Market Centre. The other authors report no conflicts of interest in this work.
References


Current perspectives in HIV post-exposure prophylaxis


65. Hendrix C, Minnis A, Gauderra V, et al. MTN-001: a Phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. 18th Conference on Retroviruses and Opportunistic Infections; February 27–March 2, 2011; Boston, MA: abstr 35LB.


